Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630396 · ClinicalTrials.gov registry record · Phase 1
Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke
A Phase 1 study of Stroke, Acute, sponsored by David Hess, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT00630396 is a Phase 1 study of Stroke, Acute that has completed, run by David Hess, MD. The registered enrollment target is 60 participants, below the 628-participant average among 25 other Stroke, Acute trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00630396, a Phase 1 study of Stroke, Acute, has completed, sponsored by David Hess, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary aim of this study is to find out which of 4 different doses of minocycline are safe and well tolerated so that we will know the optimal dose to test in future patients.
Conditions Studied
Interventions
- DRUG Minocycline
Study Locations (2)
Kentucky
- University of Kentucky - Lexington
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00630396
The ClinicalTrials.gov registry entry for NCT00630396 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 628-participant average among 25 other Stroke, Acute trials with a reported enrollment target (90% lower). The listed sponsor is David Hess, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stroke, Acute appearing as the primary indexed condition, and to 1 intervention - of which Minocycline is the first listed.
NCT00630396 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kentucky, Oregon.
Frequently Asked Questions
What is clinical trial NCT00630396 about?
NCT00630396 is a clinical study titled "Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke". The primary aim of this study is to find out which of 4 different doses of minocycline are safe and well tolerated so that we will know the optimal dose to test in future patients.
What is the current status of trial NCT00630396?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2008-05. Estimated completion is 2010-01.
What conditions does trial NCT00630396 study?
This clinical trial studies the following conditions: Stroke, Acute.
What interventions are being tested in trial NCT00630396?
The interventions under investigation include: Minocycline (DRUG).
Who is sponsoring clinical trial NCT00630396?
This trial is sponsored by David Hess, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00630396 being conducted?
This trial has 2 study locations across Kentucky, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke, Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Somatic Dysfunction in Patients With Acute Cerebrovascular Disease
RECRUITING
-
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
RECRUITING · NA
-
Focused Intensive Repeated Stepping During Inpatient Rehabilitation Poststroke - A Quality Improvement Project
RECRUITING
-
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
RECRUITING · NA
-
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
RECRUITING · NA
-
Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.